<DOC>
	<DOCNO>NCT02116231</DOCNO>
	<brief_summary>The study design compare Intensity Modulated Radiotherapy ( IMRT ) combination concurrent chemotherapy IMRT alone treatment stage II nasopharyngeal carcinoma .</brief_summary>
	<brief_title>The Role Adding Concurrent Chemotherapy IMRT Treatment Stage II Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Nasopharyngeal carcinoma ( NPC ) endemic Southern China , Southeast Asia , Arctic , mid-East/North Africa . NPC prevalence report high southern China , average 80 case per 100,000 population report year . It radiosensitive chemosensitive . The National Comprehensive Cancer Network ( NCCN ) guideline ( version 1 , 2013 ) , recommend use concurrent chemoradiotherapy ( CCRT ) without adjuvant chemotherapy ( AC ) standard treatment NPC . Recently , technique IMRT become widely use treatment nasopharyngeal carcinoma . The preliminary result show IMRT might improve rate local control quality life NPC . In retrospective study ( Ivan,2010 ) , result show IMRT without concurrent chemotherapy provide good outcome patient stage IIB NPC acceptable toxicity . Another study show Comparing IMRT alone , IMRT combination chemotherapy provide significant benefit locoregionally advanced NPC ( Su,2011 ) . With IMRT , unclear whether additional concurrent chemotherapy essential stage II nasopharyngeal carcinoma . The investigator design present study research role add concurrent chemotherapy intensity modulate radiotherapy treatment stage II NPC . The primary endpoint failure-free survival ( FFS ) .The second endpoint overall survival ( OS ) , loco-regional failure-free survival ( LFFS ) , distant metastasis failure-free survival ( DMFS ) , acute late adverse event .</detailed_description>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients newly histologically confirm nonkeratinizing ( accord WHO histologically type ) . 18 Years 70 Years Tumor stag T12N1/ T2N0 ( accord 7th AJCC edition ) , No evidence distant metastasis ( M0 ) Satisfactory performance status : Karnofsky scale ( KPS ) &gt; 70 ( Appendix I ) . Adequate marrow : leucocyte count &gt; 4×109/L , neutrophil count &gt; 2×109/L , hemoglobin &gt; 90g/L platelet count &gt; 100×109/L Normal liver function test : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) &lt; 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) &lt; 2.5×ULN , bilirubin &lt; ULN Adequate renal function : creatinine clearance &gt; 60 ml/min Patients must inform investigational nature study give write informed consent WHO Type keratinize squamous cell carcinoma basaloid squamous cell carcinoma . Age &gt; 60 &lt; 18 . Treatment palliative intent . Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . History previous RT ( except nonmelanomatous skin cancer outside intend RT treatment volume ) . Prior chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Nasopharyngeal neoplasm ; IMRT ; Concurrent chemotherapy</keyword>
</DOC>